News

Genprex Advances to Phase 2 of Acclaim-3 Trial for Reqorsa Therapy

Genprex Advances to Phase 2 of Acclaim-3 Trial for Reqorsa Therapy

Genprex Advances Clinical Trials for Cancer Treatments

Genprex, Inc. (NASDAQ: GNPX), a pioneering clinical-stage gene therapy company, has made significant strides in its efforts to combat extensive stage small cell lung cancer (ES-SCLC). The company has just completed the Phase 1 dose escalation segment of its Acclaim-3 clinical trial for Reqorsa® Gene Therapy, alongside Tecentriq®, a widely recognized treatment in oncology. With FDA Fast Track Designation already secured, Genprex is setting the stage for a promising future in cancer therapy.

Acclaim-3 Trial Overview

The Acclaim-3 clinical trial seeks to evaluate the efficacy of REQORSA in combination with Tecentriq, focusing specifically on patients who have not experienced tumor progression after initial treatment regimens. The Safety Review Committee (SRC) recently approved the transition to the Phase 2 expansion phase of this critical study.

Key Findings from Phase 1

In the Phase 1 dose escalation, the SRC reviewed comprehensive safety data, confirming that the trial did not yield any dose limiting toxicities (DLTs). As a result, the recommended Phase 2 Dose (RP2D) has been established at 0.12 mg/kg. This dosage aims to enhance treatment effectiveness while minimizing potential adverse effects. Furthermore, the SRC's endorsement allows for the enrollment of new participants in the Phase 2 phase.

Patient Responses and Clinical Benefits

One notable case highlighted within the trial showed that a patient had achieved a partial remission, defined as at least a 30% reduction in tumor size after completing two cycles of maintenance therapy. This promising response underscores the potential effectiveness of combining REQORSA with Tecentriq for those battling ES-SCLC. The insights gleaned from such patient outcomes provide hope for advancing treatment options in a field where limited alternatives remain.

Future Directions for Genprex

Looking ahead, Genprex aims to expedite the clinical development process, aiming for enrollment to begin in the second half of the study timeline. By collaborating with an extensive network of community oncology practices, Genprex plans to optimize patient enrollment rates. The innovation behind combining gene therapies showcases the company's commitment to evolving cancer treatment landscapes. Moreover, the results from the Phase 1 trial will be submitted for presentation at a notable clinical meeting in the coming year, which is expected to broaden understanding of REQORSA’s potential.

Importance of the Acclaim-3 Study

The Acclaim-3 clinical trial embodies an open-label, multi-center investigation that not only evaluates Genprex's lead candidate but also paves the way for a hopeful future for SCLC patients. The trial plans to enroll approximately 50 patients across up to 15 U.S. sites. The primary endpoint revolves around assessing the 18-week progression-free survival rate, instrumental in determining the treatment's effectiveness.

Technological Innovations Supporting Genprex

Genprex's innovative methodologies highlight the company's dedication to employing advanced techniques in gene therapy. The systemic, non-viral Oncoprex® Delivery System encapsulates gene-expressing plasmids utilizing lipid-based nanoparticles and allows for targeted delivery into tumor cells. This novel approach reflects Genprex's ongoing goal to provide groundbreaking therapies to those facing cancer and diabetes.

About Genprex, Inc.

Genprex, Inc. is a company committed to developing transformative therapies aimed at combating cancer and diabetes. The organization leverages its technological expertise to bring forth solutions that can benefit large populations not adequately served by existing treatments. With a strong focus on collaboration with top-tier research institutions, Genprex's pipeline is robust, targeting various treatment avenues through innovative designs.

Frequently Asked Questions

What is the Acclaim-3 clinical trial?

The Acclaim-3 clinical trial evaluates the effectiveness of Reqorsa Gene Therapy combined with Tecentriq in treating extensive stage small cell lung cancer.

What does the Phase 1 trial entail?

The Phase 1 trial involved dose escalation to determine the safety and best dosage for subsequent phases, with promising patient responses noted.

What is the expected outcome of the Phase 2 trial?

The Phase 2 trial aims to assess the 18-week progression-free survival rate among participants receiving combined therapies.

How does Reqorsa work?

Reqorsa utilizes a unique Oncoprex Delivery System, enabling gene therapies to target tumor cells effectively.

Can I stay updated about Genprex?

Yes, interested individuals can visit the Genprex website to sign up for press releases and stay informed on company advancements.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 29

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 166

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 89

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 101

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 93

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 74

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading

Top 5 Most Recently Viewed Articles

BlueVoyant Launches Innovative Cybersecurity Solution for Enterprises

Updated Category News Views 249

BlueVoyant Introduces a Cutting-Edge Cybersecurity Solution BlueVoyant has launched its Continuous Optimization for Microsoft Security (COMS) service, marking a significant step in enterprise cybersecurity. This innovative solution is crafted to empower organizations with advanced threat detection and optimization strategies for Microsoft Security tools. Clients benefit...

Continue Reading
Prudential Advisors Welcomes New Talent and Grows Nationally

Updated Category News Views 224

Prudential Advisors' Remarkable Growth in 2025 Prudential Advisors is on an exciting journey, having welcomed an impressive wave of experienced financial advisors, significantly bolstering their national influence. Incorporating skilled advisors managing an astounding $3 billion in client assets marks a pivotal milestone for the firm. With nearly a 9% rise in advisor...

Continue Reading
Investors Unite: Solaris Energy Faces Class Action Lawsuit

Updated Category News Views 351

Understanding the Class Action Lawsuit Against Solaris Energy Infrastructure Recent developments have brought attention to Solaris Energy Infrastructure, Inc. and its ongoing class action lawsuit. Shareholders are encouraged to stand up for their rights as allegations arise concerning the company's practices and communications with investors. Details of the Allegations...

Continue Reading
Raising Awareness for Emergency Notification System Signs

Updated Category News Views 145

Understanding Emergency Notification System Signs As part of an ongoing effort to enhance safety at railroad crossings, Operation Lifesaver, Inc. (OLI), an esteemed national nonprofit dedicated to rail safety education, is launching its inaugural Emergency Notification System (ENS) Sign Awareness Day. This event is not just a one-time notice; it's an encouragement for all...

Continue Reading
Veolia and Mistral AI Unite to Transform Ecological Management

Updated Category News Views 361

Revolutionizing Resource Management with Generative AI Veolia, a prominent name in ecological transformation, is making waves by collaborating with Mistral AI, a leader in generative artificial intelligence. Their recent strategic partnership aims to redefine the management of industrial sites, focusing on water management, waste recycling, and local energy production....

Continue Reading